Ibogaine Clinical Trials 2026

Phase I: Safety & Dosing (First-in-Human)

Small cohorts (20-80 participants) establish that a compound can be given to humans without unacceptable toxicity. For ibogaine, Phase I work has focused intensively on the cardiac QTc prolongation risk, the primary safety signal requiring resolution before broader trials. The formal Phase I record is thin: early noribogaine dosing studies, the dose-escalation arm of the Spanish ICEERS trial, and a large body of observational safety data from monitored clinics standing in for what controlled Phase I work has not yet covered.

Phase II: Efficacy Signal & Dose Optimization

Larger cohorts test whether the compound produces the intended therapeutic effect at a dose the body can tolerate. Exactly one randomized Phase II trial of ibogaine has completed: the 13-patient ICEERS methadone-tapering study in Spain (January 2025). The Stanford MISTIC veterans data is often read alongside it but is observational, not a controlled trial. The funded Texas IMPACT program is designed to produce the controlled efficacy data this phase still lacks.

Phase III: Pivotal Randomized Controlled Trials

Large multicenter RCTs (300-3,000+ participants) provide the statistical power required for regulatory approval. No ibogaine compound has reached Phase III anywhere in the world. Phase III trials require 2-5 years, $50-200M in funding, and reproducible efficacy across diverse populations. The Texas IMPACT consortium's multi-campus structure is the only infrastructure currently being built at a scale that could support eventual Phase III work.

Phase IV: Post-Market Surveillance

Ongoing safety monitoring after regulatory approval. For ibogaine, Phase IV will be critical: the cardiac risk requires long-term pharmacovigilance, drug-drug interaction data collection, and registry-based outcomes tracking at the national level. FDA will almost certainly require REMS (Risk Evaluation and Mitigation Strategy) conditions on any ibogaine approval: mandatory cardiac monitoring protocols, certified prescriber training, and restricted dispensing settings.

Where Ibogaine Stands in 2026

The first US IND for an ibogaine-class compound was accepted in April 2026 (DemeRx's oral noribogaine for alcohol use disorder), the UK's MHRA has cleared a Phase 1/2a of oral ibogaine for opioid use disorder, Texas has committed roughly $100 million to a statewide trial program now in protocol development, and on October 6, 2026 the FDA opened a public docket requesting information on ibogaine. No trial is recruiting US patients yet, and no compound is near approval. In the meantime, legal, medically supervised treatment remains available in Mexico, and MindScape operates according to the same cardiac safety standards the research protocols employ.

Cherian KN, Keynan JN, Anker L, et al. (2024). Magnesium-ibogaine therapy in veterans with traumatic brain injuries.

Nature Medicine, 30, 373-381

First randomized trial demonstrating ibogaine's efficacy in military veterans with TBI, PTSD, and alcohol/drug misuse. Catalyzed the $50M Texas IMPACT program.

Brown TK, Alper K. (2018). Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes.

American Journal of Drug and Alcohol Abuse, 44(1), 24-36

Largest observational study of ibogaine for OUD at the time. Established safety and efficacy benchmarks informing clinical trial design.

Mash DC, et al. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence.

Frontiers in Pharmacology, 9, 529

Multi-site observational data from licensed ibogaine clinics. Foundational efficacy evidence cited by every subsequent trial protocol.

Davis AK, et al. (2020). Subjective effectiveness of ibogaine treatment for problematic opioid consumption.

Journal of Psychedelic Studies, 4(1), 50-57

Patient-reported outcomes validating long-term abstinence and quality-of-life improvements one year post-treatment.

FDA approval for ibogaine is not imminent. The first US IND for an ibogaine-class compound was only accepted in April 2026 (DemeRx's oral noribogaine for alcohol use disorder), and the full pathway from IND to approval typically takes 7-12 years, so a realistic approval window opens in the 2030s and depends entirely on trial results that have not been generated yet. The signals pointing the right way are real: the Texas IMPACT program is funded at roughly $100 million, and on October 6, 2026 the FDA opened a public request for information on ibogaine (docket FDA-2026-N-10429), a step agencies take when they are seriously studying a compound's path. No ibogaine compound currently holds Breakthrough Therapy designation.

Not yet inside the United States: as of October 12, 2026 no US ibogaine trial is recruiting. The accepted DemeRx IND has not opened enrollment, and the Texas IMPACT program is still in protocol development, so the practical step is to search ClinicalTrials.gov for 'ibogaine' periodically and register interest with the IMPACT consortium when enrollment opens. When trials do recruit, common exclusion criteria include: cardiac arrhythmias or prolonged QTc interval, concurrent use of serotonergic medications (SSRIs, SNRIs), methadone or buprenorphine at high doses, history of psychosis or bipolar I disorder, and pregnancy. If you cannot wait for a trial, legal treatment in Mexico at facilities like MindScape offers immediate access to medically supervised ibogaine protocols.

Yes. Ibogaine is not classified as a controlled substance under Mexican federal law, and its administration in clinical settings is legal. MindScape Retreat in Cozumel has operated continuously since its founding, with a licensed physician (Dr. Arellano, M.D.) overseeing every treatment. Our facility uses the same cardiac monitoring protocols (12-lead EKG screening, continuous telemetry during treatment, electrolyte optimization) that clinical trials employ. Legal does not mean unregulated: our protocols exceed the safety standards of many clinical settings.

MindScape's clinical protocol mirrors the safety infrastructure of the trials in all medically critical respects: pre-treatment cardiac screening (12-lead EKG, electrolyte panel, complete metabolic panel), physician-supervised dosing, continuous cardiac monitoring throughout the experience, and trained nursing staff present around the clock. Where clinical trials use standardized dosing for research consistency, MindScape's Dr. Arellano individuates dose based on patient weight, metabolic profile, substance history, and clinical presentation, which may produce superior outcomes for complex cases. We do not participate in active clinical trials, but our data from 1,000+ treated patients informs our evidence base.

DemeRx is a US biopharmaceutical company co-founded by Dr. Deborah Mash, the researcher behind much of the foundational human ibogaine data. In April 2026 the FDA accepted DemeRx's Investigational New Drug application for DMX-1001 (oral noribogaine, ibogaine's principal active metabolite) for alcohol use disorder, the first time the FDA has authorized a US clinical trial of any ibogaine-class compound. The company separately holds UK MHRA approval for a Phase 1/2a study of DMX-1002, oral ibogaine itself, in opioid use disorder. The importance is regulatory: an accepted IND means the FDA has reviewed the preclinical safety package and will allow human dosing in the US, and whatever DemeRx's trials show will set the precedent for every ibogaine compound that follows, including natural ibogaine HCl.

Clinical trials employ rigorous safety protocols specifically designed around ibogaine's primary risk: QTc interval prolongation, which can precipitate life-threatening arrhythmias in susceptible individuals. All reputable trials require pre-treatment 12-lead EKG, electrolyte correction, exclusion of patients with cardiac contraindications, and continuous cardiac monitoring during administration. Observational data from licensed clinics (including our own 1,000+ patient dataset) shows that when these precautions are followed, serious adverse cardiac events are rare. Deaths associated with ibogaine, which are documented in the literature, have overwhelmingly occurred in uncontrolled, unmonitored settings without appropriate screening.